Bronchoscopic management of asthma, COPD and emphysema.

Authors:
Perotin JM; Dewolf M; Launois C; Dormoy V; Deslee G.

Journal:
Eur Respir Rev

Publication Year: 2021

DOI:
10.1183/16000617.0029-2020

PMCID:
PMC9488643

PMID:
33650526

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur Respir Rev

Abbreviation: Eur Respir Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
An update on diagnosis and management of obstructive sleep apnoea in the first 2 years of life.
Polytarchou A; Moudaki A; Van de Perck E and 4 more (2024) - Transparency Score: 2/6
Clinical-imaging-pathological correlation in pulmonary hypertension associated with left heart dise…
van de Veerdonk MC; Roosma L; Trip P and 4 more (2024) - Transparency Score: 2/6
Eradication treatment for <i>Pseudomonas aeruginosa</i> infection in adults with bronchiectasis: a …
Conceição M; Shteinberg M; Goeminne P and 2 more (2024) - Transparency Score: 3/6
From treatable traits to GETomics in airway disease: moving towards clinical practice.
Papi A; Faner R; Pavord I and 6 more (2024) - Transparency Score: 3/6
Lung cancer risk and occupational pulmonary fibrosis: systematic review and meta-analysis.
Krabbe J; Steffens KM; Drießen S and 1 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: J.M. Perotin has nothing to disclose.: Conflict of interest: M. Dewolf has nothing to disclose.: Conflict of interest: C. Launois has nothing to disclose.: Conflict of interest: V. Dormoy has nothing to disclose.: Conflict of interest: G. Deslee reports personal fees from BTG/PneumRx and Nuvaira, during the conduct of the study; personal fees from Chiesi, Boehringer Ingelheim, AstraZeneca and Novartis, outside the submitted work."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025